Carcinoembryonic Antigen (Cea)

Carcinoembryonic Antigen (Cea) is a protein that is produced in the fetus and is absent in healthy adults. It can be produced by carcinoma, especially colon carcinoma, but is an insensitive marker of malignancy.

Cea refers to oncofetal antigens, that is, proteins that are expressed during embryonic development, but are reexpressed in the adult body when tumors arise. It is used as an indicator of various tumors, in particular colorectal cancer, lung cancer, breast cancer and others.

An increased level of Cea in the blood may indicate the presence or recurrence of a tumor process. Determining the concentration of this marker is used to monitor the course of cancer and evaluate the effectiveness of therapy. Thus, the Cea antigen is an important diagnostic tool in oncology.

Carcinoembryonic antigen, or Carcinoembryonic Antigen (Cea), is one of the most common oncofetal antigens, which is used in oncology for the diagnosis and treatment of various tumors. This protein is produced in the fetus during pregnancy and is absent in healthy adults. However, in some types of cancer, such as colon carcinoma, Cea can be produced and become a sensitive tumor marker.

One of the main advantages of Cea is its ability to detect various types of cancer, including colon carcinoma. It can also be used to monitor the effectiveness of cancer treatment and determine tumor recurrence. However, it should be noted that Cea is not a completely accurate indicator of cancer and may produce false positive results.

It is important to note that although Cea has low sensitivity for cancer, it can be used in combination with other markers for more accurate diagnosis and treatment monitoring. Overall, Cea remains an important tool in the diagnosis and treatment of cancer, although it has its limitations.

Carcinoembryonic Antigen (CEA) is one of the most common tumor markers used in the diagnosis of colon and stomach tumors. CEA is a glycoprotein found in fetal blood. It is synthesized